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Advanced glycation end-products (AGEs) inhibit
ischemia-induced angiogenesis but are potential triggers
of neoangiogenesis that occurs in peritoneal dialysis (PD)
patients. We investigated whether the effect of glucose and
AGEs on human peritoneal mesothelial cells (HPMCs) might
alter the release of vascular endothelial growth factor (VEGF)
and subsequently the formation of capillary tubes by
human umbilical vein endothelial cells (HUVECs). HPMCs
were exposed to glucose and the glycated protein
Ne-(carboxymethyl)lysine-human serum albumin (CML-HSA)
and VEGF production was measured by reverse transcription-
polymerase chain reaction and enzyme-linked
immunosorbent assay. Capillary tube formation by HUVECs
in presence of HPMC supernatant or co-cultured with HPMC
was investigated. AGE and VEGF levels in PD effluents from
11 patients were measured. CML-HSA stimulated VEGF
production by HPMCs, Po0.001. Glucose and AGE inhibited
capillary tube formation by HUVECs, Po0.001. HPMC
supernatant potentiated capillary tube formation, Po0.001.
In co-culture with HPMC capillary tube formation was
increased, especially by HPMCs stimulated by CML-HSA,
Po0.001. Anti-VEGF antibody limited this effect, Po0.001.
Preincubation of HPMCs with anti-receptor for AGEs (RAGE)
antibody reduced capillary tube formation, Po0.001. AGE
and VEGF levels in PD effluents were increased during long
dwell time, Po0.05 and Po0.001, respectively. In a co-culture
system, we showed that VEGF production by HPMC favors
capillary tube formation through mesothelial RAGE activation
and could explain neoangiogenesis in PD patient.
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The treatment of end-stage renal failure by peritoneal dialysis
(PD) is associated with a progressive loss of efficacy owing to
increased membrane permeability and ultrafiltration fail-
ure.1,2 Fibrosis of the submesothelial layer and neoangiogene-
sis are observed.2,3 Peritoneal exposure to PD fluids (PDFs),
especially conventional poorly biocompatible PDFs which
combine non-physiological pH, high glucose concentrations,
and high levels of glucose degradation products (GDPs), is
associated with an elevated incidence of peritoneal altera-
tions.1,4 Heat sterilization of PDFs induces the formation of
GDPs such as glyoxal, methylglyoxal, 3-deoxyglucosone, and
3,4-dideoxyglucosone-3-ene which are involved in the
formation of advanced glycation end-products (AGEs).4–6
Glucose, GDPs, and AGEs have distinct and synergistic toxic
effects on human peritoneal mesothelial cells (HPMCs),
reducing cell proliferation and inducing apoptosis.7 The
binding of AGEs to the receptor for AGEs (RAGE) activates
HPMCs and potentiates vascular cell adhesion molecule
expression and leukocyte adhesion.8
Reduction in ultrafiltration capacity is related to
vascular modifications which occur after repeated peritoneal
exposure to PDFs, the consequence of a complex interaction
between cytokines and vasoactive factors.3,9 Vascular
endothelial growth factor (VEGF) is a potent proangiogenic
factor which is involved in endothelial cell proliferation
and vascular permeability.10 Local VEGF production
during PD plays a key role together with other factors
such as transforming growth factor-b1 in a process that leads
to the development of peritoneal neoangiogenesis and
fibrosis.11,12
In patients with diabetes mellitus, Ne-(carboxymethyl)
lysine-human serum albumin (CML-HSA), a high-affinity
ligand for RAGE, is potentially involved in the development
of microvascular complications.13 High AGE concentrations
observed in patients with this disease also amplify extra-
cellular matrix degradation by metalloproteinases, and may
limit the development of neoangiogenesis secondary to
ischemia.14 The relationship between neovascularisation,
glucose, and AGEs is not obvious as high glucose concentra-
tions and AGEs are factors that are known to inhibit
angiogenesis. In the present work, we hypothesized that
mesothelial cells, which undergo alterations following
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exposure to PDFs might deliver a message to endothelial
cells, which could result in neoangiogenesis. Capillary tube
formation by human umbilical vein endothelial cells
(HUVECs) was inhibited by high glucose concentrations
and AGEs (CML-HSA) in Matrigel but the supernatant of
HPMCs enhanced capillary tube formation. The capillary
tube formation was potentiated when HPMCs were stimu-
lated by CML-HSA and co-cultured with HUVECs. We
explored whether VEGF secreted by HPMCs after mesothelial
RAGE activation could result in capillary tube formation
stimulation.
RESULTS
CML-HSA enhances VEGF mRNA and protein production in a
time- and concentration-dependent manner
In HPMCs, maximum VEGF messenger RNA (mRNA)
expression and protein production were reached with 2.5
and 5 nmol/ml CML-HSA concentration, respectively (Figure
1a). HPMCs produced VEGF protein under basal conditions
(171.7716.5 pg/1 103 HPMCs). CML-HSA enhanced
VEGF mRNA expression and protein production by HPMCs
in a concentration but also in a time-dependent manner.
With the addition of 5 nmol/ml CML-HSA, optimal protein
production response was reached after a 40 h period
of stimulation (281.0712.4 pg/1 103 HPMCs; Po0.001)
(Figure 1b). No significant modification of VEGF protein
production was induced by a higher glucose concentration,
that is, 15 g/l (151.8713.5 pg/1 103 HPMCs). CML-HSA
enhanced the production of VEGF when associated with
glucose 15 g/l (311.8766.3 pg/1 103 HPMCs; Po0.01)
(Figure 1c).
As maximum VEGF protein production was achieved with
5 nmol/ml CML–HSA, this concentration was used for the
following experiments.
Endothelial cell VEGF receptor 1 and 2 regulation by
CML-HSA
When HUVECs were incubated (glucose 1 g/l) with CML-
HSA, endothelial vascular endothelial growth factor receptor
(VEGFR)-1 protein expression was significantly enhanced
(2.870.1 vs 2.270.1 pg/103 HUVECs, Po0.01).
Endothelial VEGFR-1 protein expression increase was also
observed in presence of 15 g/l glucose (Po0.05) (Figure 2).
VEGFR-2 protein was not detectable in HUVECs.
Antiangiogenic activity of glucose and CML-HSA via RAGE
In Matrigel, HUVECs spontaneously formed capillary tubes
(12.870.3/mm2; Figure 3 corresponding to the experimental
condition A shown in Figure 4). Compared with 1 g/l
glucose-containing culture medium, the ability of HUVECs
to form capillary tubes in Matrigel was significantly inhibited
by 15 g/l glucose (5.670.2/mm2; Po0.001) and CML-HSA
had no additional inhibitory effect (5.070.3/mm2). The
capillary tube formation was totally inhibited when HUVECs
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Figure 1 | Mesothelial cell VEGF mRNA expression and protein
production are stimulated by CML-HSA in a (a) concentration and
(b) time-dependent manner. HPMCs were cultured in presence or
absence CML-HSA (1.25–5 nmol/ml) during 3–40 h. VEGF mRNA
expression in HPMCs was assessed by real-time reverse
transcription-polymerase chain reaction (curve). VEGF protein
production was assessed by ELISA in culture supernatants (bars).
(c) CML-HSA in presence of glucose (15 g/l) stimulates VEGF protein
production. Results are expressed as the mean7s.e.m. of nine
determinations (three experiments performed in triplicate)
(**Po0.01; ***Po0.001).
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Figure 2 | CML-HSA stimulated VEGF-R1 expression by HUVECs.
Confluent HUVECs were incubated 40 h in culture medium (glucose
1 or 15 g/l) with CML-HSA (5 nmol/ml). VEGFR-1 protein expression
was measured by ELISA in HUVEC cell lysates. Results are the
mean7s.e.m. of two experiments performed in triplicate (*Po0.05;
**Po0.01).
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were cultured in high glucose concentration 42.5 g/l (Figure
3a). CML-HSA inhibited the formation of capillary tubes
(7.670.3/mm2; Po0.001), and anti-RAGE antibody signifi-
cantly reduced the antiangiogenic effect of CML-HSA
(10.770.4/mm2; Po0.001), whereas non-immune immuno-
globulin (Ig) G did not (Figure 3b).
VEGF produced by HPMCs stimulates capillary tube
formation
To demonstrate that inhibition of capillary tube formation
induced by glucose (15 g/l) can be partially reversed by the
addition of HPMC supernatant, HUVECs were exposed to
supernatants of HPMCs cultured with glucose 15 g/l.
Capillary tube formation was 10.170.7/mm2 (Figure 5),
whereas after the addition of anti-human VEGF antibody to
the HPMC supernatant the capillary tube formation was
reduced (8.070.4/mm2). This result suggests that VEGF
present in the HPMC supernatant was implicated in the
angiogenic mechanism (Po0.05).
To investigate the possible presence of a cross-talk
between mesothelial and endothelial cells, we developed a
co-culture system without direct contact between the two cell
types (experimental condition C shown in Figure 4). In
this system (using a 24-well plate), the spontaneous
generation of capillary tubes by HUVECs (without the
addition of cultured HPMCs) was found to be within
the same range (11.270.9/mm2, Figure 6a) as that observed
in the 96-well plate experiments (12.870.3/mm2, Figure 3).
VEGF measured by enzyme-linked immunosorbent assay
(ELISA) was not detected in the HUVEC supernatant
regardless of the presence or absence of CML-HSA, thus
ensuring that all the VEGF present in our system
was produced by HPMCs. Compared to the spontaneous
capacity of HUVECs to form capillary tubes under
basal conditions, the co-culture with unstimulated HPMCs
enhanced capillary tube formation (15.370.7/mm2;
Po0.001, Figure 6b). The stimulation of HPMCs
present in the upper compartment by CML-HSA but
not by control HSA resulted in increased capillary tube
formation by HUVECs in the lower compartment
(19.770.6/mm2; Po0.001; Figure 6d). The capillary
tube formation promoted by the co-culture of HUVECs
with stimulated HPMCs was mediated by mesothelial
RAGE, as RAGE blockade by anti-RAGE antibody limited
capillary tube development (15.470.6/mm2; Po0.001,
Figure 6e). The addition of anti-VEGF antibody to HPMCs
significantly reduced capillary tube formation by HUVECs
(15.970.7/mm2; Po0.001; Figure 6f). These results indicate
that VEGF production is stimulated by CML-HSA
through mesothelial RAGE activation, and may well be
responsible for a large proportion of the increase in capillary
tube formation.
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Figure 3 | (a) Glucose inhibits in vitro neoangiogenesis. HUVECs were
incubated 24 h with culture medium at different glucose
concentrations (1, 15, or 42.5 g/l) with or without CML-HSA (5 nmol/
ml). (b) CML-HSA inhibits via RAGE the capacity of HUVECs to form
capillary tubes. HUVECs were cultured 24 h in Matrigel with HSA or
CML-HSA (5 nmol/ml) added to the culture medium. To block the
AGE-RAGE interaction, HUVECs were preincubated 30 min with
anti-RAGE antibody (100 mg/ml). Non-immune IgG was used as
control. The results are expressed in number of capillary tubes
formed per mm2, and presented as the mean7s.e.m. of 36
determinations from six different experiments (***Po0.001).
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Figure 4 | Experimental conditions for capillary tube formation by
HUVECs. (a) HUVECs cultured in Matrigel. (b) HUVECs cultured in
Matrigel exposed to HPMC supernatant. (c) Co-culture of HUVECs in
Matrigel (lower compartment) with HPMCs on a transwell membrane
(upper compartment).
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AGE and VEGF concentrations in PD effluents
In a separate study, we found that blood AGE-protein
concentration in PD patients was 15.477.8 mg/ml at PD
initiation and increased to 20.878.3 mg/ml, 6 months later.15
In the present work, 6 weeks after PD initiation, AGE-protein
concentration in PD effluents was 25.774.1 mg/ml after short
dwell and reached 40.374.3 mg/ml after long dwell (Po0.05)
suggesting local AGE production. VEGF levels were higher in
long dwell PD effluents (35.474.3 vs 15.971.8 pg/ml,
Po0.001; Figure 7a). AGE-protein level correlated with
VEGF concentration in PD effluents (Figure 7b).
DISCUSSION
Despite the direct inhibitory effect of AGEs on capillary tube
formation by HUVECs, we demonstrated that VEGF
produced by mesothelial cells through RAGE activation led
to an increase in capillary tube formation by HUVECs. The
present study supports the hypothesis of a possible cross-talk
between AGE-stimulated HPMCs and endothelial cells,
resulting in neoangiogenesis. Higher levels of VEGF in PD
effluents after longer dwell time may be a biomarker of
HPMC alteration owing to the effect of glucose concentra-
tions and AGEs that may participate in the development of
neoangiogenesis. PDFs containing low levels of AGE pre-
cursors have the potential to slow down conventional PDF-
induced VEGF expression and AGE accumulation, as demon-
strated in rat experiments, suggesting a close correlation
between AGE concentrations and peritoneal VEGF produc-
tion.16 Immunoblotting and immunostaining studies have
previously demonstrated that VEGF colocalizes with
AGE deposits in the peritoneal membrane and is mainly
located in the endothelium lining the peritoneal blood
vessels.3,18 In the present study, AGEs were detected by
immunoassay that did not assess the presence of glycation-
free adducts which are measured by liquid chromatography-
mass spectrometry. Different compounds are classified as
being glycation products: early glycation adducts, monolysyl
adducts including CML, hydroimidazolones, bis(lysyl)imida-
zolium crosslinks, or pentosidine. In PD therapy, protein
glycation-free adducts that markedly accumulate in the
plasma of uremic patients are mainly eliminated in the
peritoneal dialysate.19,20
AGEs are involved in the development of microvascular
complications in patients with diabetes mellitus and
contribute to the deleterious effects upon ischemia-induced
neoangiogenesis.13,14 Inhibition of AGE formation could
consequently be used to stimulate collateral vessel formation
in the context of ischemia, and may constitute an alternative
therapeutic strategy to enhance new vessel growth in the
setting of diabetes. Neoangiogenesis, which occurs in the
peritoneum exposed to glucose and glycoxidation products,
appears to be mediated by a paracrine mechanism. In the co-
culture experiments, we demonstrated that in vitro HPMC
exposure to AGEs could result in a release of VEGF, which
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Figure 5 | Capillary tube formation stimulated by HPMC supernatant is reduced by preincubation with anti-VEGF antibody. (a) HUVECs
were grown for 24 h with glucose (15 g/l). (b) Capillary tube formation was stimulated 24 h by HPMC supernatant which could be reduced
by preincubation 30 min with anti-VEGF antibody (0.5 mg/ml) (c). The results of experiments are expressed in number of capillary tubes
formed per mm2, and presented as the mean7s.e.m. of 36 determinations from six different experiments (*Po0.05; ***Po0.001).
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enhances capillary tube formation and conceals the anti-
angiogenic effect of AGEs. Similarly, in the nervous system, a
dysregulation between neuronal and vascular cells contri-
butes to the development of severe disorders such as motor
neuron degeneration or Alzheimer’s disease.21 The activity of
VEGF-A, the major isoform acting on the endothelial cells
investigated in this study, is mediated mainly via two tyrosine
kinase receptors, VEGFR-1 and VEGFR-2. VEGFR-1 and
VEGFR-2 protein analysis revealed that VEGFR-1 was
upregulated by CML-HSA in HUVECs, and may participate
in endothelial cell overstimulation. Approaches to disrupt
VEGF/VEGF receptor signaling pathways range from small
molecular ATP competitive VEGF receptor inhibitors to
biological agents such as soluble receptor, anti-VEGF, and
anti-VEGF receptor antibodies. Antiangiogenic treatment
such as the use of thalidomide and protein kinase-b
inhibitors can represent an alternative treatment.22
Low-GDP PDFs preserve peritoneal integrity and may
thus improve the longevity of the peritoneal membrane.
GDPs combined with accelerated AGE formation are the
main causative factors in PDF-induced peritoneal damage.23
RAGE stimulation results in HPMC activation, which may
promote local inflammation, and is thus implicated in the
peritoneal injury found in long-term PD patients.8 Glycated
serum albumin stimulated VEGF production by HPMCs but
not glucose alone.17 In the present co-culture system that
could mimic in vivo mesothelial/endothelial VEGF cross-talk,
mesothelial cell RAGE activation resulted in increased VEGF
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Figure 6 | (Top panel) VEGF produced by HPMCs stimulates capillary tube formation by HUVECs. Formation of capillary tubes by
HUVECs in Matrigel was evaluated in a co-culture system with HPMCs. Capillary tube formation by HUVECs was measured (a) under basal
conditions and (b) in a co-culture system with unstimulated HPMCs or (c) when stimulated for 24 h by HSA or (d) CML-HSA (5 nmol/ml). (Bottom
panel) Mesothelial RAGE is involved in increased capillary tube formation. (e) For the RAGE blockade experiment, CML-HSA-stimulated HPMCs
were preincubated for 30 min with rabbit anti-RAGE antibody (100mg/ml). In other experiments, (f) mouse anti-human VEGF antibody (0.5 mg/
ml) or (g) non-immune IgG was added to the HPMC and HUVEC culture medium. The results of the experiments are expressed in terms of the
number of capillary tubes formed per mm2, and presented as the mean7s.e.m. of 36 determinations from six different experiments
(***Po0.001).
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production leading to capillary tube formation. RAGE-
deficient mice failed to develop peritoneal neoangiogenesis
and increased VEGF expression after exposure to high GDP-
containing PDFs compared to control mice.24 Animal and in
vitro studies have evidenced that AGE/RAGE interaction
blockade by soluble RAGE or anti-RAGE antibodies could
reduce the cellular and organic alterations secondary to
RAGE activation, but these molecules have not been used in
human therapy.8,25,26
The excess of reactive oxygen intermediates, oxidized
carbohydrate proteins and lipids observed in hemodialyzed
patients shows that this technique also has its limitations.
Alternatively, the blood levels of advanced oxidation protein
products (opp) can be reduced by PD treatment.15 Owing to
the shortage of kidneys available for transplantation and the
increasing number of patients with renal failure the artificial
clearance of toxins has to be adopted as the technique of
choice, and therefore needs to be improved upon.
MATERIALS AND METHODS
Cell cultures
The study was conducted in accordance with the Declaration of
Helsinki Principles, and with the rules of our institution. All the
experiments were performed using HPMCs obtained from 15
consenting donors.
HPMCs were isolated from freshly obtained omental tissue and
cultured in M199 plus 20% fetal calf serum as described previously.8
HUVECs were isolated from human umbilical cords by enzymatic
digestion with collagenase,27 grown in M199 plus 20% fetal calf
serum, and used for capillary tube formation experiments.
Preparation of CML-HSA
CML is a major lysine-derived AGE. To prepare CML-HSA, HSA
(30 mg/ml), and sodium cyanoborohydride (0.45 M) were dissolved
in sodium phosphate buffer (0.2 M; pH 7.8).28 Glyoxylic acid was
then added, and the mixture incubated for 24 h at 371C. Control
protein was prepared under the same conditions, except that
glyoxylic acid was omitted. The preparation of CML-modified
proteins was characterized by modifications in percentage, assessed
via 2,4,6-trinitrobenzenesulfonic acid and by gas chromatography-
mass spectrometry. CML-HSA and control HSA solutions were
extensively dialyzed for 48 h (1 v/100 v). To avoid any residual
sodium cyanoborohydride (62.84 Da) or glyoxylic acid (74.04 Da)
presence, the membrane cutoff was 15 000 Da. Endotoxin levels
evaluated by chromogenic Limulus assay (ACC, Falmouth, MA,
USA) amounted to o0.002 EU/mg protein in the experimental
preparations.
CML blood concentrations assessed by ELISA in diabetic patients
varied between 1.4 and 7 nmol/ml,13 and evaluated by tandem mass
spectrometry in PD patients the mean of CML concentration was
8.0173.8 nmol/ml.29 To stimulate the VEGF production by
HPMCs, we tested three different CML-HSA concentrations (1.8,
3.75, and 7.5 mg/ml of albumin) corresponding to 1.25, 2.5, and
5 nmol/ml CML-HSA, respectively.
Measurement of VEGF mRNA expression and protein pro-
duction by HPMCs
Reverse transcription-polymerase chain reaction was performed in a
20 ml reaction system with the use of the RNA Master HybProbe kit
in LightCycler technology (Roche Diagnostics, Mannheim, Ger-
many). The content of the amplification mix and the thermal cycling
conditions were set to manufacturer’s instructions. Following
oligonucleotide primers and probes were designed for human
VEGF-A (isoform VEGF165): sense 5
0-CCCTGAGATGCAGTACAT-
30; antisense 50-AGCAAGGCCCACAGGGATTT-30 (corresponding
to ex5/7); labeled probe (5’FAM, 30TAMRA) 50-ATCCTGTGTGCC
GATGCGATGCGGT-30. b2-Microglobulin served as a reference
gene: sense 50-GATGAGTATGCCTGCCGTGTG-30; antisense 50-
CAATCCAAATGCGGCATCT-30; labeled probe 50-CTCCATGA
TGCTGCTTACATGTCTCGATCCC-30. VEGF and b2-micro-
globulin transcripts were quoted from reference.30 Negative controls
excluded amplification from contaminating genomic DNA. The
relative changes in VEGF/b2-microglobulin mRNA ratio between
treated and non-treated cells were determined by the DDCt
procedure. Efficiencies of target and reference gene amplification
were comparable.
Production of VEGF protein was measured in HPMC super-
natants using a Quantikine Human VEGF165 Immunoassay system
(R&D Systems, Abingdon, Berks, UK). HPMCs (15 103/well) were
seeded and cultured in a 96-well plate for 24 h. HPMCs were
exposed during 40 h to culture medium with or without CML-HSA
(1.25, 2.5, or 5 nmol/ml). Effect of CML-HSA was also analyzed in
culture medium containing 15 g/l D-glucose (Sigma, St Louis, MO,
USA). VEGF protein concentration was also measured in PD
effluents.
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Figure 7 | (a) AGE-protein and VEGF concentrations are increased in
PD effluents after long dwell time. AGE-protein and VEGF
concentrations assessed by ELISA in PD effluents from 11 PD patients
were analyzed after short or long dwell time in the peritoneum for
conventional lactate-based PDFs (15 g/l glucose) (*Po0.05;
***Po0.001 for AGE-protein and VEGF, respectively). (b) AGE-protein
correlated with VEGF concentration in PD effluents. Correlation
between AGE-protein and VEGF concentrations in PD effluents
(short and long dwell) was analyzed by the Pearson correlation
test.
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Anti-VEGF antibodies
Neutralizing mouse anti-human VEGF monoclonal antibody (IgG,
Sigma) was used in the capillary tube formation experiments (at 0.1,
0.25, 0.5, and 1 mg/ml). The highest blocking effect was achieved
with 0.5 mg/ml. Mouse non-immune IgG was used as control
(Sigma).
Anti-RAGE antibody production
Anti-RAGE antibody was obtained using purified recombinant rat
RAGE to immunize rabbits.25 HPMCs or HUVECs were preincubated
with anti-RAGE IgG for 30 min at a concentration of 100mg/ml
previously determined as the concentration totally blocking RAGE-
ligand interaction.8 Rabbit non-immune IgG was used as control
(Sigma).
Expression of VEGF receptors
VEGF-A activity is mainly mediated via two tyrosine kinase receptors,
VEGFR-1 and VEGFR-2. HUVECs were grown until confluence, then
stimulated for 40 h with CML-HSA. VEGFR-1 and -2 protein
expression was measured by ELISA in HUVEC cell lysates using a
Quantikine human soluble VEGFR-1 or VEGFR-2 immunoassay
(R&D Systems).
Capillary tube formation in Matrigel
The property of HUVECs to spontaneously form capillary tubes in
Matrigel basement membrane matrix (Becton Dickinson, San Diego,
CA, USA) was used to assess the effect of glucose and CML-HSA as a
model for angiogenesis (Figure 4a). HUVECs (40 103/well) were
cultured in Matrigel in a 96-well plate (M199þ 10% fetal calf
serum) for 24 h with glucose (1 or 15 g/l), with HSA or CML-HSA.
To investigate RAGE involvement, a series of experiments were
performed in the presence of anti-RAGE antibody or non-immune
IgG. Capillary tube formation was quantified by counting the
number of capillary tube structures formed per mm2 using
videomicroscopy linked to a computerized analytical system.
To demonstrate that VEGF produced by HPMCs and present in
the supernatant could alter capillary tube formation, HPMC
supernatant was added to the HUVEC cultures (Figure 4b). HPMCs
were cultured for 24 h and then exposed for 40 h to culture medium
containing D-glucose (15 g/l). The HPMC supernatants preincu-
bated or not with anti-human VEGF antibody were added to the
HUVECs, and their effect on the HUVEC-induced formation of
capillary tubes in Matrigel was tested.
Co-culture system
HPMCs (30 103/chamber) were initially cultured in M199þ 10%
fetal calf serum until confluence on a polyester membrane in an
intercup chamber (Becton Dickinson) before the experiments.
HUVECs were seeded in a Matrigel matrix in a 24-well plate. After
HUVEC culture in Matrigel (3 h), the confluent HPMCs cultured in
the membrane of the intercup chamber were added to the wells
(Figure 4c). HPMCs were stimulated beforehand for 30 min with
CML-HSA. For the RAGE blockade experiment, HPMCs were
preincubated with anti-RAGE antibody or non-immune IgG for
30 min before CML-HSA stimulation. In some experiments, anti-
VEGF antibody or non-immune IgG was added to the culture
medium just before and during the stimulation period. During the
co-culture period CML-HSA was still present in the HPMC
supernatant, allowing passage into the HUVEC culture medium.
After 24 h of co-culture, the number of capillary tubes was counted
using a microscope linked to a computerized video system.
Effluents from PD patients
PD effluent from 11 patients (56714.2 years old) treated by PD for
6 weeks and receiving conventional heat-sterilized lactate-buffered
PDFs (pH 5.5, glucose 15 g/l) were collected after short (4.270.8 h)
or long (9.871.9 h) dwell times in the peritoneal cavity. Mean
glucose peritoneal equilibration test and daily dextrose exposure
(DDE) were measured as described previously.15 glucose peritoneal
equilibration test was 0.470.1 and DDE was 114712.7 g/day.
After collection, the effluents were centrifuged for 7 min at 150 g,
and the supernatants were collected into sterile tubes then stored at
801C until the measurements of AGE and VEGF concentrations
were performed.
AGE measurement in PD effluents
AGE-protein concentration present in the PD effluents was
determined by competitive ELISA.28 Briefly, glycated proteins
(glycated RNase) were used for immunization in hens and IgY
were obtained by differential polyethylene glycol precipitation and
purified by cryoalcohol treatment (Agrobio, La Ferte´ St Aubin,
France). Antibody specificity has been described previously.28 The
results were expressed in mg/ml AGE-protein.
Statistical analysis
The results of VEGF production by HPMCs and capillary tube
formation were presented as the mean7s.e.m. Statistical signifi-
cance was determined using one-way analysis of variance followed
by the parametric Dunnett’s test. Variations in the VEGF and AGE-
protein measurements during PDF dwell time were assessed by the
Wilcoxon signed rank test for paired comparisons.31 Correlation
between the AGE-protein and VEGF concentration in PD effluents
was analyzed by the Pearson correlation test. A P-value of under 0.05
was considered as being statistically significant.
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